

# INDEX

Note: Page numbers of article titles are in **boldface** type.

- Actin-cytoskeleton, integrin interaction with, 223-224
- Adhesion, cellular, integrins in. See *Integrins*.
- Adult T-cell lymphoma-leukemia syndrome, flow cytometric analysis in, 262
- Allophycocyanin, in flow cytometry, 246
- Amniocentesis, in granulomatous disease detection, 298
- Antibodies, monoclonal. See *Monoclonal antibodies*.
- to HIV. See under *Human immunodeficiency virus*.
- Antibody-dependent cellular cytotoxicity, in HIV infection, 317
- Antigens. See also specific antigen, e.g., *p24 antigen*.
- in HIV infection, 308, 310, 317-318
- to proliferating cells, in cell cycle analysis, 179, 190-192
- Autoradiography, in cell cycle analysis, 172-173
- B-cell prolymphocytic leukemia, flow cytometric analysis in, 260
- Blood, lysis of, for flow cytometry, 266-268
- Bromodeoxyuridine incorporation method, in cell cycle analysis, 179, 190
- Canadian Association of Pathologists, workload recording method of, 339-341
- Cancer, cell proliferation markers in. See *Cell proliferation markers*.
- immunotherapy in, monoclonal antibodies in. See under *Monoclonal antibodies*.
- integrins role in, 220-222
- Carcinogenesis, cell proliferation markers and, 164-168
- cDNA sequencing, in granulomatous disease, 297
- Cell(s), adhesion of, integrins in. See *Integrins*.
- differentiation of, integrins in, 222-223
- fixation of, for flow cytometry, 273
- labeling of, for flow cytometry, 269-273
- signal transduction pathways of, integrin interaction with, 224-226
- Cell cycle, cell proliferation markers and, 169-180
- phases of, 169-171
- quantitative measurement of, 171-180
- Cell proliferation antigens. See *Proliferating cell antigens*.
- Cell proliferation markers, 163-199
- carcinogenesis and, 164-168
- cell cycle and, 169-180
- clinical significance of, 180-192
- growth kinetics and, 168-169
- measurement of, antigen analysis in, 190-192
- flow cytometry in, 186-190
- halogenated pyrimidine incorporation in, 190
- nuclear organizer region technique in, 192
- metastasis and, 166-168, 182-184
- prognostic implications of, 180-182, 186-190
- therapeutic implications of, 184-186
- tumor biology and, 164-169
- tumor heterogeneity and, 168
- Chemotherapy, cell proliferation markers in, 184-186
- monoclonal antibody-drug conjugates (chemoimmunoconjugates) in, 207-210

- Chorionic villus sampling, in  
granulomatous disease detection, 298
- Chronic lymphocytic leukemia, flow  
cytometric analysis in, 258, 260
- Clustering, in test selection, 363–370
- College of American Pathologists,  
workload recording method of. See  
*Workload recording method.*
- Cryopreservation, for flow cytometry,  
268–269
- Culture, of HIV, 318–319
- Cytophilic antibody, in flow cytometry, of  
lymphocyte markers, 262
- Data collection, for test selection, 356  
in workload recording method, 344–345
- Data organization, for test selection. See  
*Test selection.*
- 3-Deamino-3-(4-morpholinyl)-  
doxorubicin-monoclonal antibody  
conjugate, in cancer immunotherapy,  
208–209
- Decision making, for test selection. See  
*Test selection.*
- Dendrograms, in test selection, 361
- 4-Desacetylvinblastine-3-  
carboxyhydrazide-monoclonal  
antibody conjugate, in cancer  
immunotherapy, 209–210
- Disintegrins, 230
- DNA, halogenated pyrimidine  
incorporation into, in cell cycle  
analysis, 179  
identification of, in HIV, 319–320  
nucleolar organizer regions of, in cell  
proliferation measurement, 179–  
180, 192  
quantitation in cell cycle analysis, 173–  
180  
clinical significance of, 180–192
- DNA hybridization, in HIV testing, 319–  
320
- DNA index, in cell cycle analysis, 174–176
- DNA ploidy. See *Ploidy.*
- DNA-specific dyes, in cell cycle analysis,  
173–179
- Drugs, monoclonal antibody conjugates  
with, 207–210
- Dyes, DNA-specific, in cell cycle analysis,  
173–179
- Effector cells, in immunotherapy,  
activation of, 202–205  
redirection to tumor sites, 205–207
- ELISA. See *Enzyme-linked immunosorbent  
assay.*
- Embryonic development, integrins in,  
222–223
- Endometrial carcinoma stage I prognostic  
index, 189
- Endothelial cells, integrins associated  
with, 219
- Enzyme-linked immunosorbent assay, in  
HIV testing, 311–314, 317–318
- Epidermal growth factor receptors, in  
tumor, monoclonal antibodies  
directed to, 210–211
- Epithelial cells, integrins associated with,  
218–220
- Ethidium bromide, in cell cycle analysis,  
174
- Feulgen staining technique, in static  
cytophotometry, 178
- Fibrinogen, integrin recognition of, 226–  
227, 229
- Fibronectin, integrin recognition of, 226–  
227
- Ficoll-Hypaque technique, 268
- Flow cytometry, in cell cycle analysis,  
174–177, 186–190  
in HIV testing, 318  
in lymphocyte marker analysis, 237–275  
antibody labeling techniques in, 263–  
266  
biohazards precautions in, 274  
cell fixation for, 273  
cell gating settings for, 243–244  
cell labeling for, 269–273  
compensation settings for, 241, 243  
computer data acquisition in, 239  
fluorochromes for, 245–246, 271–273  
in B-cell prolymphocytic leukemia,  
260  
in chronic lymphocytic leukemia, 258,  
260  
in follicular center cell lymphoma, 260  
in hairy cell leukemia, 260  
in plasmacytoid lymphocytic lym-  
phoma, 260  
in T-cell chronic lymphoproliferative  
disease, 260, 262  
instrumentation for, 238–245  
monoclonal antibodies for, 246–247  
procedure for, 263–274  
quality control in, 244–245, 273–274  
results interpretation in, 247, 255–263  
settings in, 239–244  
specimen handling in, 266–269  
technical problems in, 262–263  
voltage gain settings for, 239–241

- in proliferating-cell antigen analysis, 190-192
  - Fluorescein, in flow cytometry, 245, 263-264
  - Fluorochromes, in cell cycle analysis, 173-179
    - in flow cytometry, of lymphocyte markers, 245-246, 271-273
  - Follicular center cell lymphoma, flow cytometric analysis in, 260
  
  - Glioblastoma multiforme, integrins in, 220-221
  - Glioma, immunotherapy in, monoclonal antibodies in, 209-210
  - Glucose-6-phosphate dehydrogenase deficiency, defective respiratory burst in, 284-285
  - Glutathione reductase deficiency, defective respiratory burst in, 285
  - Granulocyte-macrophage colony-stimulating factor, in cancer immunotherapy, 205
  - Granulomatous disease, 277-305
    - carrier state of, diagnosis of, 292-293
    - classification of, 280-281, 284, 292, 294
    - clinical features of, 289, 292-293
    - incidence of, 280
    - infections in, 288-289, 292
    - pathogenesis of, 280-288
    - phagocyte respiratory burst and, defective, 280-288
      - normal, 277-280
      - regulation of, 279-280
    - testing in, cDNA sequencing, 297
    - NADPH oxidase component gene characterization, 293, 295
    - Northern analysis, 296
    - polymerase chain reaction, 297
    - prenatal, 297-299
    - Southern analysis, 296
  - Growth factor receptors, in tumor, monoclonal antibodies directed to, 210-211
  
  - Hairy cell leukemia, flow cytometric analysis in, 260
  - Halogenated pyrimidine incorporation method, in cell cycle analysis, 179, 190
  - HIV. See *Human immunodeficiency virus*.
  - Human immunodeficiency virus, genetics of, 308
    - testing for, 307-335
  - antibody-dependent cellular cytotoxicity and, 317
  - antibody detection methods, 310-317
  - antigen detection assays, 317-318
  - direct detection methods, 317-320
  - enzyme-linked immunosorbent assay, 311-314
  - hybridization techniques, 320
  - in infants, 322-324
  - indirect immunofluorescence antibody assay, 316
  - peptide immunoassays, 313-314
  - polymerase chain reaction, 319-320
  - prenatal, 323-324
  - radioimmunoprecipitation antibody assay, 316-317
  - rapid agglutination screening assays, 314
  - RNA detection, 319-320
  - serologic stages and, 308, 310
  - type 1 vs. type 2, 314
  - viral culture methods, 318-319
  - viral DNA/RNA detection methods, 319-320
  - virus characteristics and, 307-308
  - Western blot test, 314-316
- Hybridization techniques, in HIV testing, 319-320
- 
- Image analysis, in cell cycle analysis, 186-190
  - in DNA content analysis, 177-180
- Immunofluorescence antibody assay, in HIV testing, 316
- Immunology, cell proliferation markers in, 163-199
  - in cancer immunotherapy, 201-216
  - in granulomatous disease, 277-305
  - in HIV testing, 307-335
  - integrin-mediated cell adhesion, 217-236
  - lymphocyte markers in, 237-275
- Immunotherapy, cancer, monoclonal antibodies in. See under *Monoclonal antibodies*.
- Immunotoxins, in cancer, 207-209
- Indirect immunofluorescence antibody assay, in HIV testing, 316
- Infants, HIV testing in, 322-324
- Infection(s), in leukocyte adhesion deficiency, 287, 289
- Information management, for test selection. See *Test selection*.
- Integrins, 217-236
  - activation on cell surface, 229-230
  - antagonists of, 230-231
  - cell type specificity of, 218-220

- Integrins (*Continued*)  
 in cancer, 220–222  
 in cell differentiation, 222–223  
 in cell signal mediation, 224–226  
 in embryonic development, 222–223  
 in melanoma, 221–222  
 interaction with actin-cytoskeleton, 223–224  
 interaction with ligand, structural basis for, 227–229  
 recognition of specific sites in adhesive proteins by, 226–227  
 regulation on cell surface, 229–230  
 structures of, 217–218
- Ki-67 antigen, quantitation of, 191–192
- Laboratory management, test selection decisions. *See Test selection.*  
 workload recording method, 339–352  
 Laboratory Management Index Program, 349
- Large granular lymphocytic leukemia, flow cytometric analysis in, 262
- Latex agglutination screening assays, for HIV, 314
- Leukemias, flow cytometric analysis in, 258, 260, 262
- Leukocyte(s), integrins associated with, 219, 229
- Leukocyte adhesion deficiency, vs. granulomatous disease, 285, 287
- Lymphocytes, CD antigens of, monoclonal antibodies to, in flow cytometry, 247  
 flow cytometric analysis of. *See Flow cytometry, in lymphocyte marker analysis.*
- Lymphoma, flow cytometric analysis in, 260
- Lysis, blood, for flow cytometry, 266–268
- Malignancy. *See Cancer.*
- Markers, cell proliferation. *See Cell proliferation markers.*  
 lymphocyte. *See Flow cytometry, in lymphocyte marker analysis.*
- Medical record, consensible, 383–386
- Melanoma, immunotherapy in, monoclonal antibodies in, 203–205, 208–211, 213  
 integrins associated with, 219, 221–222
- Metastasis, cell proliferation markers and, 166–168, 182–184  
 inhibition of, integrin antagonists in, 230
- Monoclonal antibodies, in cancer immunotherapy, 201–216  
 bispecific, 205–207  
 directed to growth factor receptors, 210–211  
 effector cell activation in, 202–205  
 effector cell redirection to tumor sites by, 205–207  
 genetically engineered, 211–213  
 toxic agent conjugation by, 207–210  
 in cell cycle analysis, 179  
 in flow cytometry, of lymphocyte markers, 246–247, 263–266
- Mouse/human chimeric anti-GD2 antibody ch14.18, in cancer immunotherapy, 203–205
- Mycosis fungoides, flow cytometric analysis in, 262
- Myeloperoxidase, deficiency of, defective respiratory burst in, 285, 287
- NADPH oxidase, component genes of, characterization of, 293, 295–299  
 respiratory burst and, defective, 280–281, 284–285  
 normal, 277, 279–280  
 regulation of, 279–280
- Neuroblastoma, immunotherapy in, monoclonal antibodies in, 203–205, 212–213
- Neutrophil glucose-6-phosphate dehydrogenase deficiency, defective respiratory burst in, 284–285
- Nitroblue tetrazolium reduction test, in granulomatous disease, 298
- Northern blot, in granulomatous disease, 296
- Nucleolar organizer regions, in cell proliferation measurement, 179–180, 192
- Oncogenes, 164, 166
- Oncology. *See Cancer.*
- p24 antigen, in HIV infection, antibodies to, 308, 310  
 direct detection of, 318
- PCNA. *See Proliferating-cell nuclear antigen.*
- Pediatric patients, HIV testing in, 322–324

- Peptides, as antigens in HIV testing, 313–314
- Peridinin chlorophyll, in flow cytometry, 246
- Personnel, management of. See *Workload recording method*.
- Phagocytosis, respiratory burst in, defective, 280–281, 284–285  
normal, 277, 279–280  
regulation of, 279–280
- Phycobiliproteins, in flow cytometry, 245–246, 264–266
- Plasmacytoid lymphocytic leukemia, flow cytometric analysis in, 260
- Ploidy, clinical significance of, prognostic, 180–182, 186–190  
therapeutic, 186–191  
flow cytometry analysis of, 174–177
- Polymerase chain reaction, in granulomatous disease, 297  
in HIV testing, 319–320
- Pregnancy, HIV testing in, 323–324
- Prenatal testing, for granulomatous disease, 297–299  
for HIV, 323–324
- Productivity, in workload recording method, 345–347
- Proliferating cell antigens, in cell cycle analysis, 190–192  
types of, 179
- Proliferating cell nuclear antigen/cyclin, quantitation of, 192
- Proliferative index, in cell cycle analysis, 176
- Propidium iodide, in cell cycle analysis, 174
- Pulse exposure techniques, in cell cycle analysis, 173
- Pyrimidines, halogenated, in cell cycle analysis, 179, 190
- Radioimmunoprecipitation antibody assay, in HIV testing, 316–317
- Radioisotope studies, in cell cycle analysis, 172–173
- Radionuclides, in cancer immunotherapy, monoclonal antibody conjugation to, 207
- Rapid latex agglutination screening assays, for HIV, 314
- Respiratory burst, in phagocytosis. See under *Phagocytosis*.
- RNA detection techniques, in HIV testing, 319–320
- S-phase fraction, in cell cycle analysis, 176  
prognostic implications of, 181–182
- Safety precautions, in flow cytometry, 274
- Southern blot, in granulomatous disease, 296
- Static cytophotometry, in DNA content analysis, 177–180
- Statistical mechanics, analogies to test selection decision making, 372–375
- Superoxide radical, release of, in phagocytosis. See *Phagocytosis, respiratory burst in*.
- Sézary syndrome, flow cytometric analysis in, 262
- T-cell lymphoproliferative disease, flow cytometric analysis in, 260, 262
- T-cell prolymphocytic leukemia, flow cytometric analysis in, 262
- Test selection, 353–388  
for consensable medical record, 383–386  
*NP*-complete problems in, 380–383  
primary classifications for, 355–370  
data acquisition for, 356  
dendrograms in, 361  
entropy in, 372–375  
indicative sentences in, 357–358  
information loss in, 362–363  
likelihood identification in, 376–377  
linkage clustering in, 363–370  
logical comprehension in, 378  
mapping in, 361  
matrices in, 358  
Port Royal logic in, 370–375  
probability in, 361  
realistic comprehension in, 378–379  
relative frequency classification in, 376–377  
scaling in, 361–363  
separatory clustering in, 363–370  
statistical mechanics analogies, 372–375  
sufficiency of information in, 377–378  
theoretic comprehension in, 379–380  
truth tables in, 358–362  
uncertainty in, 361  
usefulness in, 377–378  
variables in, 357–358  
quality improvement in, 354
- Thrombosis, inhibition of, integrin antagonists in, 230
- Thymidine labeling method, in cell cycle analysis, 173  
prognostic implications of, 180–181
- Toxins, monoclonal antibody-drug conjugates with, 207–209
- Truth tables, in test selection, 358–362
- Tumor(s). See also *Cancer*.

- Tumor(s) (*Continued*)  
  biology of, carcinogenesis, 164–168  
  growth kinetics, 168–169  
  heterogeneity, 168  
  metastasis. See *Metastasis*.  
  growth suppression in, monoclonal antibodies in, 210–211
- Tumor markers. See *Cell proliferation markers*.
- Vinblastine derivative-monoclonal antibody conjugate, in cancer immunotherapy, 209–210
- Viper venom peptides, as integrin antagonists, 230
- Vitronectin, integrins associated with, 229
- Western blot test, in HIV testing, 314–316
- Workload Productivity Comparison Program, 349
- Workload recording method, 339–352  
  applications of, 347–348  
  constant hour tracking in, 344  
  data collection in, 344–345  
  historical background of, 340–341  
  implementation of, 344–345  
  management and, 349  
  nonworkload activity tracking in, 343–344  
  principles of, 341–343  
  productivity ratio recommendations for, 345–347  
  time studies with, 343–344  
  units used in, 341–343